Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sill

Showing results (61-70 of 149) with videos related to

Pageof 15
Sort By:
Neuro-Oncology|November 11, 2020
An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastomaThomas K Albert, Marta Interlandi, Martin Sill, et al.
International Journal of Cancer|April 12, 2022
A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsisUmar Khalid, Milena Simovic, Linda A Hammann, et al.
Neuro-Oncology|October 17, 2017
Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastomaPhilipp Kickingereder, Ulf Neuberger, David Bonekamp, et al.
Acta Neuropathologica Communications|June 27, 2025
Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohortTom T Fischer, Kendra K Maaß, Pitithat Puranachot, et al.
Acta Neuropathologica Communications|November 10, 2020
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusionsDouglas A Mata, Jamal K Benhamida, Andrew L Lin, et al.
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Neuro-Oncology|June 2, 2021
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastomaKent A Riemondy, Sujatha Venkataraman, Nicholas Willard, et al.
Acta Neuropathologica|April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratificationJack Goddard, Jemma Castle, Emily Southworth, et al.
Brain Pathology (Zurich, Switzerland)|June 27, 2015
Papillary Tumor of the Pineal Region: A Distinct Molecular EntityStephanie Heim, Martin Sill, David T W Jones, et al.
Acta Neuropathologica|November 18, 2019
YAP1-fusions in pediatric NF2-wildtype meningiomaPhilipp Sievers, Jason Chiang, Daniel Schrimpf, et al.
Pageof 15

Showing results (61-70 of 149) with videos related to

Sort By:
Pageof 15
Neuro-Oncology|November 11, 2020
An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastomaThomas K Albert, Marta Interlandi, Martin Sill, et al.
International Journal of Cancer|April 12, 2022
A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsisUmar Khalid, Milena Simovic, Linda A Hammann, et al.
Neuro-Oncology|October 17, 2017
Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastomaPhilipp Kickingereder, Ulf Neuberger, David Bonekamp, et al.
Acta Neuropathologica Communications|June 27, 2025
Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohortTom T Fischer, Kendra K Maaß, Pitithat Puranachot, et al.
Acta Neuropathologica Communications|November 10, 2020
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusionsDouglas A Mata, Jamal K Benhamida, Andrew L Lin, et al.
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Neuro-Oncology|June 2, 2021
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastomaKent A Riemondy, Sujatha Venkataraman, Nicholas Willard, et al.
Acta Neuropathologica|April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratificationJack Goddard, Jemma Castle, Emily Southworth, et al.
Brain Pathology (Zurich, Switzerland)|June 27, 2015
Papillary Tumor of the Pineal Region: A Distinct Molecular EntityStephanie Heim, Martin Sill, David T W Jones, et al.
Acta Neuropathologica|November 18, 2019
YAP1-fusions in pediatric NF2-wildtype meningiomaPhilipp Sievers, Jason Chiang, Daniel Schrimpf, et al.
Pageof 15